The aim of this study was the successful utilization of the positively charged nanocrystals (NCs) of Tedizolid Phosphate (TZP) (0.1% /) for topical ocular applications. TZP belongs to the 1, 3-oxazolidine-2-one class of antibiotics and has therapeutic potential for the treatment of many drug-resistant bacterial infections, including eye infections caused by MRSA, penicillin-resistant and vancomycin-resistant . However, its therapeutic usage is restricted due to its poor aqueous solubility and limited ocular availability. It is a prodrug and gets converted to Tedizolid (TDZ) by phosphatases in vivo. The sterilized NC was subjected to antimicrobial testing on Gram-positive bacteria. Ocular irritation and pharmacokinetics were performed in rabbits. Around a 1.29 to 1.53-fold increase in antibacterial activity was noted for NC against the , and MRSA (SA-6538) as compared to the TZP-pure. The NC-AqS was "practically non-irritating" to rabbit eyes. There was around a 1.67- and 1.43 fold increase in t (h) and C (ngmL) while there were 1.96-, 1.91-, 2.69- and 1.41-times increases in AUC,AUC,AUMC and MRT, respectively, which were found by NC as compared to TZP-AqS in the ocular pharmacokinetic study. The clearance of TDZ was faster (11.43 mLh) from TZP-AqS as compared to NC (5.88 mLh). Relatively, an extended half-life (t; 4.45 h) of TDZ and the prolonged ocular retention (MRT; 7.13 h) of NC was found, while a shorter half-life (t; 2.66 h) of TDZ and MRT(t; 5.05 h)was noted for TZP-AqS, respectively. Cationic TZP-NC could offer increased transcorneal permeation, which could mimic the improved ocular bioavailability of the drug in vivo. Conclusively, NC of TZP was identified as a promising substitute for the ocular delivery of TZP, with better performance as compared to its conventional AqS.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325164 | PMC |
http://dx.doi.org/10.3390/molecules27144619 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!